

Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/G0E55D483F0CEN.html>

Date: March 2023

Pages: 104

Price: US\$ 3,660.00 (Single User License)

ID: G0E55D483F0CEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Eosinophilic Granulomatosis with Polyangiitis Treatment market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Eosinophilic Granulomatosis with Polyangiitis Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Eosinophilic Granulomatosis with Polyangiitis Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Eosinophilic Granulomatosis with Polyangiitis Treatment is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Eosinophilic Granulomatosis with Polyangiitis Treatment players cover Teva Pharmaceutical Industries, GlaxoSmithKline, Genentech, Baxter Healthcare, F. Hoffmann-La Roche, Cephalon, Amgen, Sanofi S.A. and Koninklijke DSM N.V, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

LPI (LP Information)' newest research report, the "Eosinophilic Granulomatosis with

"Polyangiitis Treatment Industry Forecast" looks at past sales and reviews total world Eosinophilic Granulomatosis with Polyangiitis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Eosinophilic Granulomatosis with Polyangiitis Treatment sales for 2023 through 2029. With Eosinophilic Granulomatosis with Polyangiitis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Eosinophilic Granulomatosis with Polyangiitis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Eosinophilic Granulomatosis with Polyangiitis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eosinophilic Granulomatosis with Polyangiitis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Eosinophilic Granulomatosis with Polyangiitis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eosinophilic Granulomatosis with Polyangiitis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eosinophilic Granulomatosis with Polyangiitis Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Eosinophilic Granulomatosis with Polyangiitis Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Steroids

Immunosuppressant

Biologics

Immune Globulins

Segmentation by application

Hospitals

Clinics

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Teva Pharmaceutical Industries

GlaxoSmithKline

Genentech

Baxter Healthcare

F. Hoffmann-La Roche

Cephalon

Amgen

Sanofi S.A.

Koninklijke DSM N.V

AstraZeneca

Novartis International AG

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2018-2029

2.1.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029

2.2 Eosinophilic Granulomatosis with Polyangiitis Treatment Segment by Type

2.2.1 Steroids

2.2.2 Immunosuppressant

2.2.3 Biologics

2.2.4 Immune Globulins

2.3 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type

2.3.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)

2.3.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)

2.4 Eosinophilic Granulomatosis with Polyangiitis Treatment Segment by Application

2.4.1 Hospitals

2.4.2 Clinics

2.4.3 Others

2.5 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application

2.5.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)

2.5.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)

3 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENT MARKET SIZE BY PLAYER

3.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Players

3.1.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Players (2018-2023)

3.1.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Players (2018-2023)

3.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENT BY REGIONS

4.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Regions (2018-2023)

4.2 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth (2018-2023)

4.3 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth (2018-2023)

4.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth (2018-2023)

4.5 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2018-2023)

5.2 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023)

5.3 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by

Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2018-2023)

6.2 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023)

6.3 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023)

6.4 China

6.5 Japan

6.6 Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment by Country (2018-2023)

7.2 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023)

7.3 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment by Region (2018-2023)

8.2 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023)

8.3 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENT MARKET FORECAST

10.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Regions (2024-2029)

10.1.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Regions (2024-2029)

10.1.2 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast

10.1.3 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast

10.1.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast

10.1.5 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast

10.2 Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Country (2024-2029)

10.2.1 United States Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast

10.2.2 Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast

10.2.3 Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast

10.2.4 Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast

10.3 APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Region (2024-2029)

- 10.3.1 China Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
- 10.3.2 Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
- 10.3.3 Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
- 10.3.4 Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
- 10.3.5 India Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
- 10.3.6 Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
- 10.4 Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Country (2024-2029)
 - 10.4.1 Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
 - 10.4.2 France Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
 - 10.4.3 UK Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
 - 10.4.4 Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
 - 10.4.5 Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
- 10.5 Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Region (2024-2029)
 - 10.5.1 Egypt Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
 - 10.5.2 South Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
 - 10.5.3 Israel Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
 - 10.5.4 Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
 - 10.5.5 GCC Countries Eosinophilic Granulomatosis with Polyangiitis Treatment Market Forecast
- 10.6 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Type (2024-2029)
- 10.7 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 Teva Pharmaceutical Industries

11.1.1 Teva Pharmaceutical Industries Company Information

11.1.2 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

- 11.1.3 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 Teva Pharmaceutical Industries Main Business Overview
- 11.1.5 Teva Pharmaceutical Industries Latest Developments
- 11.2 GlaxoSmithKline
 - 11.2.1 GlaxoSmithKline Company Information
 - 11.2.2 GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
 - 11.2.3 GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.2.4 GlaxoSmithKline Main Business Overview
 - 11.2.5 GlaxoSmithKline Latest Developments
- 11.3 Genentech
 - 11.3.1 Genentech Company Information
 - 11.3.2 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
 - 11.3.3 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.3.4 Genentech Main Business Overview
 - 11.3.5 Genentech Latest Developments
- 11.4 Baxter Healthcare
 - 11.4.1 Baxter Healthcare Company Information
 - 11.4.2 Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
 - 11.4.3 Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.4.4 Baxter Healthcare Main Business Overview
 - 11.4.5 Baxter Healthcare Latest Developments
- 11.5 F. Hoffmann-La Roche
 - 11.5.1 F. Hoffmann-La Roche Company Information
 - 11.5.2 F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered
 - 11.5.3 F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)
 - 11.5.4 F. Hoffmann-La Roche Main Business Overview
 - 11.5.5 F. Hoffmann-La Roche Latest Developments
- 11.6 Cephalon
 - 11.6.1 Cephalon Company Information
 - 11.6.2 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Offered

11.6.3 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.6.4 Cephalon Main Business Overview

11.6.5 Cephalon Latest Developments

11.7 Amgen

11.7.1 Amgen Company Information

11.7.2 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Offered

11.7.3 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.7.4 Amgen Main Business Overview

11.7.5 Amgen Latest Developments

11.8 Sanofi S.A.

11.8.1 Sanofi S.A. Company Information

11.8.2 Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Offered

11.8.3 Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.8.4 Sanofi S.A. Main Business Overview

11.8.5 Sanofi S.A. Latest Developments

11.9 Koninklijke DSM N.V

11.9.1 Koninklijke DSM N.V Company Information

11.9.2 Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment

Product Offered

11.9.3 Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.9.4 Koninklijke DSM N.V Main Business Overview

11.9.5 Koninklijke DSM N.V Latest Developments

11.10 AstraZeneca

11.10.1 AstraZeneca Company Information

11.10.2 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Product

Offered

11.10.3 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.10.4 AstraZeneca Main Business Overview

11.10.5 AstraZeneca Latest Developments

11.11 Novartis International AG

11.11.1 Novartis International AG Company Information

11.11.2 Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

11.11.3 Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, Gross Margin and Market Share (2018-2023)

11.11.4 Novartis International AG Main Business Overview

11.11.5 Novartis International AG Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 2. Major Players of Steroids
- Table 3. Major Players of Immunosuppressant
- Table 4. Major Players of Biologics
- Table 5. Major Players of Immune Globulins
- Table 6. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 7. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023) & (\$ Millions)
- Table 8. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)
- Table 9. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)
- Table 10. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023) & (\$ Millions)
- Table 11. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)
- Table 12. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Players (2018-2023) & (\$ Millions)
- Table 13. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Player (2018-2023)
- Table 14. Eosinophilic Granulomatosis with Polyangiitis Treatment Key Players Head office and Products Offered
- Table 15. Eosinophilic Granulomatosis with Polyangiitis Treatment Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- Table 16. New Products and Potential Entrants
- Table 17. Mergers & Acquisitions, Expansion
- Table 18. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Regions 2018-2023 & (\$ Millions)
- Table 19. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Regions (2018-2023)
- Table 20. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Country/Region (2018-2023) & (\$ millions)
- Table 21. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue

Market Share by Country/Region (2018-2023)

Table 22. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2018-2023) & (\$ Millions)

Table 23. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Country (2018-2023)

Table 24. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 25. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)

Table 26. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 27. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)

Table 28. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2018-2023) & (\$ Millions)

Table 29. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Region (2018-2023)

Table 30. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 31. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)

Table 32. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 33. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)

Table 34. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Country (2018-2023) & (\$ Millions)

Table 35. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Country (2018-2023)

Table 36. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 37. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)

Table 38. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 39. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)

Table 40. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Region (2018-2023) & (\$ Millions)

Table 41. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Region (2018-2023)

Table 42. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Type (2018-2023) & (\$ Millions)

Table 43. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)

Table 44. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size by Application (2018-2023) & (\$ Millions)

Table 45. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)

Table 46. Key Market Drivers & Growth Opportunities of Eosinophilic Granulomatosis with Polyangiitis Treatment

Table 47. Key Market Challenges & Risks of Eosinophilic Granulomatosis with Polyangiitis Treatment

Table 48. Key Industry Trends of Eosinophilic Granulomatosis with Polyangiitis Treatment

Table 49. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 50. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share Forecast by Regions (2024-2029)

Table 51. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 52. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 53. Teva Pharmaceutical Industries Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 54. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 55. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 56. Teva Pharmaceutical Industries Main Business

Table 57. Teva Pharmaceutical Industries Latest Developments

Table 58. GlaxoSmithKline Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 59. GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 60. GlaxoSmithKline Main Business

Table 61. GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 62. GlaxoSmithKline Latest Developments

Table 63. Genentech Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 64. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 65. Genentech Main Business

Table 66. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 67. Genentech Latest Developments

Table 68. Baxter Healthcare Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 69. Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 70. Baxter Healthcare Main Business

Table 71. Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 72. Baxter Healthcare Latest Developments

Table 73. F. Hoffmann-La Roche Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 74. F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 75. F. Hoffmann-La Roche Main Business

Table 76. F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 77. F. Hoffmann-La Roche Latest Developments

Table 78. Cephalon Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 79. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 80. Cephalon Main Business

Table 81. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 82. Cephalon Latest Developments

Table 83. Amgen Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 84. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 85. Amgen Main Business

Table 86. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$

million), Gross Margin and Market Share (2018-2023)

Table 87. Amgen Latest Developments

Table 88. Sanofi S.A. Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 89. Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 90. Sanofi S.A. Main Business

Table 91. Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 92. Sanofi S.A. Latest Developments

Table 93. Koninklijke DSM N.V Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 94. Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 95. Koninklijke DSM N.V Main Business

Table 96. Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 97. Koninklijke DSM N.V Latest Developments

Table 98. AstraZeneca Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 99. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 100. AstraZeneca Main Business

Table 101. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 102. AstraZeneca Latest Developments

Table 103. Novartis International AG Details, Company Type, Eosinophilic Granulomatosis with Polyangiitis Treatment Area Served and Its Competitors

Table 104. Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offered

Table 105. Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 106. Novartis International AG Main Business

Table 107. Novartis International AG Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth Rate 2018-2029 (\$ Millions)

Figure 6. Eosinophilic Granulomatosis with Polyangiitis Treatment Sales by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Figure 7. Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Market Share by Country/Region (2022)

Figure 8. Eosinophilic Granulomatosis with Polyangiitis Treatment Sales Market Share by Country/Region (2018, 2022 & 2029)

Figure 9. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type in 2022

Figure 10. Eosinophilic Granulomatosis with Polyangiitis Treatment in Hospitals

Figure 11. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market: Hospitals (2018-2023) & (\$ Millions)

Figure 12. Eosinophilic Granulomatosis with Polyangiitis Treatment in Clinics

Figure 13. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market: Clinics (2018-2023) & (\$ Millions)

Figure 14. Eosinophilic Granulomatosis with Polyangiitis Treatment in Others

Figure 15. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market: Others (2018-2023) & (\$ Millions)

Figure 16. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application in 2022

Figure 17. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share by Player in 2022

Figure 18. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Regions (2018-2023)

Figure 19. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2018-2023 (\$ Millions)

Figure 20. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2018-2023 (\$ Millions)

Figure 21. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size

2018-2023 (\$ Millions)

Figure 22. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2018-2023 (\$ Millions)

Figure 23. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Value Market Share by Country in 2022

Figure 24. United States Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Region in 2022

Figure 29. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type in 2022

Figure 30. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application in 2022

Figure 31. China Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Country in 2022

Figure 38. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)

Figure 39. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)

Figure 40. Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)

- Figure 41. France Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 42. UK Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 43. Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 44. Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 45. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Region (2018-2023)
- Figure 46. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Type (2018-2023)
- Figure 47. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share by Application (2018-2023)
- Figure 48. Egypt Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 49. South Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 50. Israel Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 51. Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 52. GCC Country Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Growth 2018-2023 (\$ Millions)
- Figure 53. Americas Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)
- Figure 54. APAC Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)
- Figure 55. Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)
- Figure 56. Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)
- Figure 57. United States Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)
- Figure 58. Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)
- Figure 59. Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)
- Figure 60. Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size

2024-2029 (\$ Millions)

Figure 61. China Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 62. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 63. Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 65. India Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 66. Australia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 67. Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 68. France Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 69. UK Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 70. Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 71. Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 72. Spain Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 75. Israel Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size 2024-2029 (\$ Millions)

Figure 78. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share Forecast by Type (2024-2029)

Figure 79. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Growth (Status and Outlook) 2023-2029

Product link: <https://marketpublishers.com/r/G0E55D483F0CEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0E55D483F0CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

